Back
Supernus Pharmaceuticals, Inc. 10K Form
Sell
34
SUPN
Supernus Pharmaceuticals, Inc.
Last Price:
$45.07
Seasonality Move:
-0.27%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-08 | 10Q | SUPN/Supernus Pharmaceuticals, Inc. Quarterly |
| 2023-11-08 | 10Q | SUPN/Supernus Pharmaceuticals, Inc. Quarterly |
| 2023-08-08 | 10Q | SUPN/Supernus Pharmaceuticals, Inc. Quarterly |
| 2023-05-09 | 10Q | SUPN/Supernus Pharmaceuticals, Inc. Quarterly |
| 2022-11-09 | 10Q | SUPN/Supernus Pharmaceuticals, Inc. Quarterly |
| 2022-08-08 | 10Q | SUPN/Supernus Pharmaceuticals, Inc. Quarterly |
Receive SUPN News And Ratings
See the #1 stock for the next 7 days that we like better than SUPN
SUPN Financial Statistics
Sales & Book Value
| Annual Sales: | $661.8M |
|---|---|
| Cash Flow: | $-61.8M |
| Price / Cash Flow: | 35.94 |
| Annual Sales: | $18.38 |
| Price / Book: | 2.46 |
Profitability
| EPS (TTM): | -0.34080 |
|---|---|
| Net Income (TTM): | $-19.1M |
| Gross Margin: | $503.5M |
| Return on Equity: | -1.84% |
| Return on Assets: | -1.37% |
Supernus Pharmaceuticals, Inc. Earnings Forecast
Key Supernus Pharmaceuticals, Inc. Financial Ratios
-
The Gross Profit Margin over the past 18 years for SUPN is 76.08%.
-
The Selling, General & Administrative Expenses for SUPN have been equal to 48.59% of Gross Profit Margin.
-
The Research & Development expenses have been 16.07% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of SUPN is 11.16% of Total Revenues.
-
Per Share Earnings over the last 18 years have been positive in 9 years.
Supernus Pharmaceuticals, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | SUPN |
| CUSIP: | 868459 |
| Website: | supernus.com |
Debt
| Debt-to-Equity Ratio: | 0.04 |
|---|---|
| Current Ratio: | 1.8 |
| Quick Ratio: | 1.37 |
Price-to-Earnings
| Trailing P/E Ratio: | 34.17 |
|---|---|
| Forward P/E Ratio: | 10.62 |
SUPN Technical Analysis vs Fundamental Analysis
Sell
34
Supernus Pharmaceuticals, Inc. (SUPN)
is a Sell
Is Supernus Pharmaceuticals, Inc. a Buy or a Sell?
-
Supernus Pharmaceuticals, Inc. stock is rated a SellThe current Supernus Pharmaceuticals, Inc. [SUPN] share price is $45.10. The Score for SUPN is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.